Ameriprise
PRAX icon

Ameriprise’s Praxis Precision Medicines PRAX Stock Holding History

Ameriprise’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.5M Buy
64,295
+33,075
+106% +$10.5M ﹤0.01% 1480
2026
Q1 		$10.1M Buy
31,220
+8,505
+37% +$2.63M ﹤0.01% 1921
2025
Q4 		$6.7M Buy
+22,715
New +$4.23M ﹤0.01% 2225
2025
Q2 		– Sell
-5,408
Closed -$205K – 4093
2025
Q1 		$205K Buy
5,408
+2,181
+68% +$136K ﹤0.01% 3787
2024
Q4 		$248K Buy
+3,227
New +$233K ﹤0.01% 3791
2023
Q1 		– Sell
-3,647
Closed -$130K – 4021
2022
Q4 		$130K Buy
3,647
+1
+0% +$31 ﹤0.01% 3779
2022
Q3 		$124K Buy
+3,646
New +$182K ﹤0.01% 3791

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Ameriprise's PRAX Position: Q2 2026 in Review

Ameriprise increased its Praxis Precision Medicines (PRAX) stake by 106% in Q2 2026, buying an estimated $10.5M and bringing the position to 64,295 shares worth $21.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1480.

Ameriprise first reported a position in PRAX in Q3 2022 and has held it in 7 quarters since. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Ameriprise held 64,295 shares of Praxis Precision Medicines worth $21.5M as of Q2 2026.
  • Ameriprise bought 33,075 Praxis Precision Medicines shares in Q2 2026, an estimated $10.5M.
  • Praxis Precision Medicines made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #1480 holding.
  • Ameriprise first reported a position in Praxis Precision Medicines in Q3 2022 and has held it in 7 quarters since.
  • 309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.